Who is the CEO of Pharmicell?

According to the DART company overview, Pharmicell's representative director is 김현수 (name as registered in Korean). The company was founded on 1968-08-20.

Where is Pharmicell listed?

Pharmicell trades on the Korea Exchange KOSPI market under the ticker 005690. Its fiscal year ends in December.

Does Pharmicell pay a dividend?

Yes. For fiscal 2025, Pharmicell paid a cash dividend of ₩50 per common share, a 0.3% yield as stated in its annual report. The prior year's dividend was ₩20.

Does Pharmicell have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue +30% (latest quarterly revenue up more than 30% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year). 2 more signals are shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as Pharmicell?

Under the Korean Standard Industrial Classification recorded on DART, Pharmicell is grouped with 134 other listed companies in electronic components. The most covered in Korean news over the past 30 days are Samsung Electro-mechanics, LG Display and LG Innotek.

Pharmicell KRX:005690KOSPI

파미셀 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked18since Sep 11

In Q2 2026, Pharmicell reported revenue of ₩39.0bn, up 45.7% year on year, and operating profit of ₩13.2bn. Pharmicell (파미셀) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 18 with 1 article.

Filing signals Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Supply contract Share pledge Screener

Pharmicell quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩39.0bn	+45.7%	₩13.2bn margin 33.9%	₩10.4bn
Q1 2026	₩36.7bn	+35.7%	₩13.1bn margin 35.6%	₩11.7bn
Q4 2025 derived	₩34.6bn	+61.2%	₩9.6bn margin 27.8%	₩15.7bn
Q3 2025	₩25.6bn	+75.7%	₩8.1bn margin 31.7%	₩8.8bn
Q2 2025	₩26.8bn	+50.3%	₩8.2bn margin 30.5%	₩7.4bn
Q1 2025	₩27.0bn	+146.3%	₩8.4bn margin 31.0%	₩8.5bn
Q4 2024 derived	₩21.5bn	+62.5%	₩3.1bn margin 14.6%	₩4.2bn
Q3 2024	₩14.6bn	+19.9%	₩1.3bn margin 8.8%	₩714m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Pharmicell top stories 2 weeks, by number of outlets

1
파미셀, 두산에 전자재료 소재 74억원 공급
1 outlets · 1 articlesFirst report Oct 18 12:44 비건뉴스

Latest Pharmicell news Korean headlines

Oct 1812:44

Major파미셀, 두산에 전자재료 소재 74억원 공급
비건뉴스
Oct 1414:27

Major파미셀, 두산에 74억 전자재료용 소재 공급
뉴시스경제Order / supply contract
Oct 1412:23

Major[공시] 파미셀 단일판매ㆍ공급계약체결
스페셜타임스Order / supply contract
Oct 1412:03

MajorBreaking파미셀, 두산과 74억원 규모 전자재료용 소재 공급계약…지난해 매출액의 6.49%
CBC뉴스Order / supply contractDoosan
Oct 1307:36

[오늘의 IR] 현대백화점·아이엘·파미셀 등
이투데이Hyundai Department Store IL
Oct 714:57

"해외 사업협력 기회 모색"…파미셀, 'CPHI' 참가
뉴시스경제
Oct 710:08

파미셀, CPHI 밀란서 핵산·의약품 소재 선보여…글로벌 고객사 확대 추진
한국경제글로벌테크놀로지
Oct 709:35
파미셀, CPHI 밀라노 참가…핵산의약품 소재 사업 확대
이데일리
1 more on this story · 1 outlets
- 파미셀, CPHI 밀라노 참가…핵산의약품 소재 사업 확대이데일리 · Oct 7 09:34
Oct 709:34
파미셀, 'CPHI Milan 2026' 참가…"글로벌 협력 강화"
뉴스핌글로벌테크놀로지
1 more on this story · 1 outlets
- 프레스티지바이오파마, 글로벌 전시회 ‘CPHI Milan 2026’ 참가더바이오 · Oct 7 10:17
Oct 709:27

Major파미셀, CPHI서 바이오 소재 공급 확대 논의…글로벌 고객사 미팅
PRESS9Order / supply contract글로벌테크놀로지
Oct 706:32
[시선강탈] 엘앤에프 vs 이수페타시스 vs 파미셀, 공략법은?
MTNIsupetasys L&F
1 more on this story · 1 outlets
- [시선강탈] 엘앤에프 vs 이수페타시스 vs 파미셀, 공략법은?머니투데이 · Oct 7 06:40
Oct 609:27

줄기세포주, 실적보다 미래 가치 집중… HLB생명과학·파미셀 주가 '신바람'
핀포인트뉴스HLB Life Science
Sep 1811:38

파미셀 주가, 9월 18일 장중 12,910원 11.49% 상승
중앙이코노미뉴스
Sep 1811:29

파미셀 주가, 급등세... 왜?
금강일보
Sep 1714:15

Featured파미셀, 두산 'CCL 1조 베팅' 최대 수혜…엔비디아 공급망 핵심 원료 '독점' 부각
프라임경제Doosan
Sep 1607:00

[혁신형 인증 영향도] 파미셀, 약가인하 '충격' 크지 않은 배경은
FETV

Articles per day 2 weeks

118

Company profile

CEO: 김현수
Industry: Electronic components
Founded: 1968-08-20
Fiscal year-end: December
Head office: 서울특별시 강남구
Website: pharmicell.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Pharmicell dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩50	0.3%	–
FY2024	₩20	0.2%	–
FY2023	–	–	–

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

김현수11.72%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Electronic components

All in industry

Company	Latest quarter op. profit	Articles 30d
Samsung Electro-mechanics	₩440bn	417
LG Display	−₩108bn	354
LG Innotek	₩246bn	270
Hanwha Systems	₩104bn	237
Doosan	₩488bn	70
Daeduck Electronics	₩70.3bn	66
Simmtech	₩62.9bn	51
Korea Circuit	₩19.3bn	47

Compare Pharmicell side by side with these companies

Pharmicell DART filings

Oct 1411:54

Supply contract 단일판매ㆍ공급계약체결
Contracts & investment
Oct 1209:08

Investor relations event 기업설명회(IR)개최(안내공시)
Other
Oct 815:14

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Pharmicell FAQ

Who is the CEO of Pharmicell?: According to the DART company overview, Pharmicell's representative director is 김현수 (name as registered in Korean). The company was founded on 1968-08-20.
Where is Pharmicell listed?: Pharmicell trades on the Korea Exchange KOSPI market under the ticker 005690. Its fiscal year ends in December.
What were Pharmicell's latest quarterly results?: In Q2 2026, Pharmicell reported revenue of ₩39.0bn, up 45.7% year on year, and operating profit of ₩13.2bn. Figures come from reports filed on DART.
Does Pharmicell pay a dividend?: Yes. For fiscal 2025, Pharmicell paid a cash dividend of ₩50 per common share, a 0.3% yield as stated in its annual report. The prior year's dividend was ₩20.
Does Pharmicell have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue +30% (latest quarterly revenue up more than 30% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year). 2 more signals are shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as Pharmicell?: Under the Korean Standard Industrial Classification recorded on DART, Pharmicell is grouped with 134 other listed companies in electronic components. The most covered in Korean news over the past 30 days are Samsung Electro-mechanics, LG Display and LG Innotek.